139 related articles for article (PubMed ID: 1444684)
1. Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients.
Gertz MA; Kyle RA; O'Fallon WM
Arch Intern Med; 1992 Nov; 152(11):2245-50. PubMed ID: 1444684
[TBL] [Abstract][Full Text] [Related]
2. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.
Bergesio F; Ciciani AM; Manganaro M; Palladini G; Santostefano M; Brugnano R; Di Palma AM; Gallo M; Rosati A; Tosi PL; Salvadori M;
Nephrol Dial Transplant; 2008 Mar; 23(3):941-51. PubMed ID: 17951308
[TBL] [Abstract][Full Text] [Related]
3. Secondary systemic amyloidosis: response and survival in 64 patients.
Gertz MA; Kyle RA
Medicine (Baltimore); 1991 Jul; 70(4):246-56. PubMed ID: 2067409
[TBL] [Abstract][Full Text] [Related]
4. Renal amyloidosis followed more than 5 years: report of 12 cases.
Kaaroud H; Boubaker K; Béji S; Abderrahim E; Moussa FB; Turki S; Goucha R; Hedri H; El Younsi F; Kheder A; Maiz HB
Transplant Proc; 2004; 36(6):1796-8. PubMed ID: 15350480
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney.
Gertz MA; Leung N; Lacy MQ; Dispenzieri A; Zeldenrust SR; Hayman SR; Buadi FK; Dingli D; Greipp PR; Kumar SK; Lust JA; Rajkumar SV; Russell SJ; Witzig TE
Nephrol Dial Transplant; 2009 Oct; 24(10):3132-7. PubMed ID: 19403931
[TBL] [Abstract][Full Text] [Related]
6. Chronic dialysis in patients with systemic amyloidosis: the experience in northern Italy.
Moroni G; Banfi G; Montoli A; Bucci A; Bertani T; Ravelli M; Pozzi C; Leonelli M; Lupo A; Volpi A
Clin Nephrol; 1992 Aug; 38(2):81-5. PubMed ID: 1516284
[TBL] [Abstract][Full Text] [Related]
7. The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.
Bird JM; Fuge R; Sirohi B; Apperley JF; Hunter A; Snowden J; Mahendra P; Milligan D; Byrne J; Littlewood T; Fegan C; McQuaker G; Pagliuca A; Johnson P; Rahemtulla A; Morris C; Marks DI;
Br J Haematol; 2006 Aug; 134(4):385-90. PubMed ID: 16822294
[TBL] [Abstract][Full Text] [Related]
8. Primary systemic amyloidosis with delayed progression to multiple myeloma.
Rajkumar SV; Gertz MA; Kyle RA
Cancer; 1998 Apr; 82(8):1501-5. PubMed ID: 9554527
[TBL] [Abstract][Full Text] [Related]
9. Survival estimates for 683 patients starting dialysis from 1970 through 1989: identification of risk factors for survival.
Mailloux LU; Bellucci AG; Napolitano B; Mossey T; Wilkes BM; Bluestone PA
Clin Nephrol; 1994 Aug; 42(2):127-35. PubMed ID: 7955575
[TBL] [Abstract][Full Text] [Related]
10. Among therapy modalities of end-stage renal disease, renal transplantation improves survival in patients with amyloidosis.
Ozdemir BH; Ozdemir FN; Sezer S; Sar A; Haberal M
Transplant Proc; 2006 Mar; 38(2):432-4. PubMed ID: 16549140
[TBL] [Abstract][Full Text] [Related]
11. Renal involvement in systemic amyloidosis.
Browning M; Banks R; Tribe C; Bacon P; Hollingworth P; Kingswood C; Poulding J; Harrison P; Mackenzie JC
Proc Eur Dial Transplant Assoc; 1983; 20():595-602. PubMed ID: 6657678
[TBL] [Abstract][Full Text] [Related]
12. Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients.
Park MA; Mueller PS; Kyle RA; Larson DR; Plevak MF; Gertz MA
Medicine (Baltimore); 2003 Sep; 82(5):291-8. PubMed ID: 14530778
[TBL] [Abstract][Full Text] [Related]
13. The short- and long-term impact of multi-disciplinary clinics in addition to standard nephrology care on patient outcomes.
Curtis BM; Ravani P; Malberti F; Kennett F; Taylor PA; Djurdjev O; Levin A
Nephrol Dial Transplant; 2005 Jan; 20(1):147-54. PubMed ID: 15585514
[TBL] [Abstract][Full Text] [Related]
14. Renal function at the time of renal biopsy as a predictor of prognosis in patients with primary AL-type amyloidosis.
Osawa Y; Kawamura K; Kondo D; Imai N; Ueno M; Nishi S; Iino N; Okada M; Suzuki Y; Hoshino S; Yamazaki H; Kishimoto H; Shimada H; Yamagishi T; Ishiyama T; Narita I; Gejyo F
Clin Exp Nephrol; 2004 Jun; 8(2):127-33. PubMed ID: 15235929
[TBL] [Abstract][Full Text] [Related]
15. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
[TBL] [Abstract][Full Text] [Related]
16. Comparison of long-term survival between hemodialysis and peritoneal dialysis.
Maiorca R; Cancarini GC; Brunori G; Zubani R; Camerini C; Manili L; Movilli E
Adv Perit Dial; 1996; 12():79-88. PubMed ID: 8865878
[TBL] [Abstract][Full Text] [Related]
17. Dialyzer membrane permeability and survival in hemodialysis patients.
Chauveau P; Nguyen H; Combe C; Chêne G; Azar R; Cano N; Canaud B; Fouque D; Laville M; Leverve X; Roth H; Aparicio M;
Am J Kidney Dis; 2005 Mar; 45(3):565-71. PubMed ID: 15754279
[TBL] [Abstract][Full Text] [Related]
18. Nodular amyloidosis: review and long-term follow-up of 16 cases.
Moon AO; Calamia KT; Walsh JS
Arch Dermatol; 2003 Sep; 139(9):1157-9. PubMed ID: 12975157
[TBL] [Abstract][Full Text] [Related]
19. [Predictors of early death during dialysis].
Caravaca F; Arrobas M; Pizarro JL; Cancho B; Cubero JJ; Espárrago JF; García MC; Sánchez-Casado E
Nefrologia; 2001; 21(3):274-82. PubMed ID: 11471308
[TBL] [Abstract][Full Text] [Related]
20. [Renal involvement in amyloidosis. Clinical outcomes, evolution and survival].
Esteve V; Almirall J; Ponz E; García N; Ribera L; Larrosa M; Andreu X; García M
Nefrologia; 2006; 26(2):212-7. PubMed ID: 16808259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
